Bharat Kumar Reddy Sanapalli

Dr. Bharat Kumar Reddy Sanapalli

Pharmacology, SVKM's NMIMS, Hyderabad, India
orcid
Assistant Professor

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
Bharat Kumar Reddy SanapalliBharat Kumar Reddy Sanapalli
Bharat Kumar Reddy Sanapalli
VSVidyasrilekha Sanapalli
Vidyasrilekha Sanapalli
MSMantosh Kumar Singh
Mantosh Kumar Singh
PKPraveen T. Krishnamurthy
Praveen T. Krishnamurthy
VKVeera Venkata Satyanarayana Reddy REDDY Karri
Veera Venkata Satyanarayana Reddy REDDY Karri
The treatment of diabetic wounds (DWs) is always challenging for the medical community because of its multifaceted pathophysiology. Due to practical and ethical considerations, direct studies of therapeutic interventions on human subjects are limited. Thus, it is ideal for performing studies on animals having less genetic and biological variability. An ideal DW model should progress toward reproducibility, quantifiable interpretation, therapeutic significance, and effective translation into clinical use. In the last couple of decades, various animal models were developed to examine the complex cellular and biochemical process of skin restoration in DW healing. Also, these models were used to assess the potency of developed active pharmaceutical ingredients and formulations. However, many animal models lack studying mechanisms that can appropriately restate human DW, stay a huge translational challenge. This review discusses the available animal models with their significance in DW experiments and their limitations, focusing on levels of proof of effectiveness in selecting appropriate models to restate the human DW to improve clinical outcomes. Although numerous newer entities and combinatory formulations are very well appreciated preclinically for DW management, they fail in clinical trials, which may be due to improper selection of the appropriate model. The major future challenge could be developing a model that resembles the human DW environment, can potentiate translational research in DW care.

21 August 2019 in Advances in Wound Care
Verified
Journal Article
Closed access
JNJawahar Natarajan
Jawahar Natarajan
Bharat Kumar Reddy SanapalliBharat Kumar Reddy Sanapalli
Bharat Kumar Reddy Sanapalli
MBMehjabeen Bano
Mehjabeen Bano
SSSACHIN Kumar SINGH
SACHIN Kumar SINGH
MGMonica Gulati
Monica Gulati
VKVeera Venkata Satyanarayana Reddy REDDY Karri
Veera Venkata Satyanarayana Reddy REDDY Karri
Diabetic wound is a major problem that often needs amputation of the concerned organ in patients suffering from diabetes. In diabetes, the prolonged phase of inflammation obstructs the further phases of healing which, in turn, lead to improper healing of the wounds in diabetes. Pioglitazone (Pio) hydrochloride is an antidiabetic drug with reported anti-inflammatory properties. The aim of this study was to develop a Pio-nanostructured lipid carrier (Pio-NLC)-loaded collagen/chitosan (COL-CS) scaffold and evaluate its healing ability in diabetic wounds. The results of characterization of composite scaffolds reveal that cross-linked scaffolds possess optimum porosity, low matrix degradation, and sustained drug release compared with noncross-linked scaffolds. The in vitro studies reveal that the Pio-NLC-COL-CS scaffold was biocompatible and enhanced cell growth compared with control and NLC-COL-CS. Using the streptozotocin-induced diabetic wound model, significantly ( p < 0.001) higher rates of wound contraction in Pio-NLC-COL-CS scaffold-treated group were observed in comparison with that in control and NLC-COL-CS-treated group. The enzyme-linked immunosorbent assay results indicate a significant ( p < 0.001) decrease of matrix metalloproteinases-9 levels in the Pio-NLC-COL-CS-treated group compared with those in control group. Use of nanostructured lipid carrier (Pio-NLC-COL-CS) scaffold can prove to be a promising strategy for local treatment for diabetic wounds.

1 January 2018 in Nanobiomedicine
Verified
Journal Article
Open access
Aninidta DeAninidta De
Aninidta De
NDNAGASAMY VENKATESH DHANDAPANI
NAGASAMY VENKATESH DHANDAPANI
MSM Senthil
M Senthil
Bharat Kumar Reddy SanapalliBharat Kumar Reddy Sanapalli
Bharat Kumar Reddy Sanapalli
RSR Shanmugham
R Shanmugham
VKVeera Venkata Satyanarayana Reddy REDDY Karri
Veera Venkata Satyanarayana Reddy REDDY Karri
Drug delivery to the brain is challenging because of the low permeability of blood–brain barrier, and therefore, optimum concentration of chemotherapeutics in the target area specifically for glioblastoma, an aggressive brain tumor, opens a new path of research. To achieve the goal, the oral alkylating agent temozolomide was incorporated into niosomes, and the surface was modified with chlorotoxin, a small 36 amino acid peptide discovered from the venom of scorpion Leiurus quinquestriatus. Active targeting using nanosized particles facilitates an increase in the accumulation of drugs in the cerebri by 3.04-folds. Temozolomide-loaded niosomes were prepared using conventional thin-film hydration method and characterized. Niosomes coated with chlorotoxin were produced with the size of 220 ± 1.45 nm with an entrapment efficiency of 79.09 ± 1.56%. Quantitative tissue distribution studies indicate enhanced permeation of the drug into the brain because of surface modification with less deposition in the highly perfused organs.

22 November 2022 in Antibiotics
Verified
Journal Article
Open access
PDF file
Bharat Kumar Reddy SanapalliBharat Kumar Reddy Sanapalli
Bharat Kumar Reddy Sanapalli
Akram AshamesAkram Ashames
Akram Ashames
Dilep Kumar SigalapalliDilep Kumar Sigalapalli
Dilep Kumar Sigalapalli
ASAfzal Shaik
Afzal Shaik
RBRichie Bhandare
Richie Bhandare
VSVidyasrilekha Sanapalli
Vidyasrilekha Sanapalli
Fused pyridines are reported to display various pharmacological activities, such as antipyretic, analgesic, antiprotozoal, antibacterial, antitumor, antifungal, anti-inflammatory, and antiapoptotic. They are widely used in the field of medicinal chemistry. Imidazopyridines (IZPs) are crucial classes of fused heterocycles that are expansively reported on in the literature. Evidence suggests that IZPs, as fused scaffolds, possess more diverse profiles than individual imidazole and pyridine moieties. Bacterial infections and antibacterial resistance are ever-growing risks in the 21st century. Only one IZP, i.e., rifaximin, is available on the market as an antibiotic. In this review, the authors highlight strategies for preparing other IZPs. A particular focus is on the antibacterial profile and structure–activity relationship (SAR) of various synthesized IZP derivatives. This research provides a foundation for the tuning of available compounds to create novel, potent antibacterial agents with fewer side effects.

12 January 2021 in Drug Development Research
Verified
Journal Article
Closed access
PDF file
LMLavanya Mude
Lavanya Mude
Bharat Kumar Reddy SanapalliBharat Kumar Reddy Sanapalli
Bharat Kumar Reddy Sanapalli
AVAnoop Narayanan V
Anoop Narayanan V
SSSachin Kumar Singh
Sachin Kumar Singh
VKVeera Venkata Satyanarayana Reddy REDDY Karri
Veera Venkata Satyanarayana Reddy REDDY Karri

2 August 2021 in RSC Advances
Verified
Journal Article
Open access
PDF file
Bharat Kumar Reddy SanapalliBharat Kumar Reddy Sanapalli
Bharat Kumar Reddy Sanapalli
VSVidyasrilekha Sanapalli
Vidyasrilekha Sanapalli
SJSrikanth Jupudi
Srikanth Jupudi
VKVeera Venkata Satyanarayana Reddy REDDY Karri
Veera Venkata Satyanarayana Reddy REDDY Karri
MMP-9 is a calcium-dependent zinc endopeptidase that plays a crucial role in various diseases and is a ubiquitous target for many classes of drugs. The availability of MMP-9 crystal structure in combination with aryl sulfonamide anthranilate hydroxamate inhibitor facilitates to accentuate the computer-aided screening of MMP-9 inhibitors with the presumed binding mode. In the current study, ligand-based pharmacophore modeling and 3D-QSAR analysis were performed using 67 reported MMP-9 inhibitors possessing pIC50 in the range of 5.221 to 9.000. The established five-point hypothesis model DDHRR_1 was statistically validated using various parameters R2 (0.9076), Q2 (0.8170), and F value (83.5) at a partial least square of four. Hypothesis validation and enrichment analysis were performed for the generated hypothesis. Further, Y-scrambling and Xternal validation using mean-absolute error-based criteria were performed to evaluate the reliability of the model. Docking in the XP mode and binding free energy was calculated for 67 selected ligands to explore the key binding interactions and binding affinity against the MMP-9 enzyme. Additionally, high-throughput virtual screening was carried out for 2.3 million chemical molecules to explore the potential virtual hits, and their predicted activity was calculated. Thus, the results obtained aid in developing novel MMP-9 inhibitors with significant activity and binding affinity.